Source: PharmaLeaders

Jecure Therapeutics: Versant Ventures launches biotechnology firm Jecure Therapeutics

Versant Ventures has launched Jecure Therapeutics, a biotechnology firm focused on the discovery of novel therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis.The post Versant Ventures launches biotechnology firm Jecure Therapeutics appeared first on PharmaLeaders.com.

Read full article »
Jecure Therapeutics's Competitors | Jecure Therapeutics's News | Jecure Therapeutics's Financials
Stay up-to-date with the latest news on Jecure
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Jeffrey A. Stafford's photo - President & CEO of Jecure

President & CEO

Jeffrey A. Stafford

CEO Approval Rating

81/100

Read more
Stay up-to-date with the latest news on Jecure